vendredi 15 décembre 2017

Onco Actu du 15 décembre 2017

4.12 Biopsies liquides

Liquid Biopsy Results Differed Substantially Between Two Providers [Johns Hopkins]

Roche’s Jennifer Cook Appointed CEO of Grail [Xconomy]

4.2 Dép., diag. & prono. - Génome

Proper data sharing in genomic medicine a top priority [PHG Foundation]

5.10 Traitements - Essais

First-in-class ERK1/2 Inhibitor Safe, Shows Early Efficacy in Patients With Advanced Solid Tumors [AACR]

5.12.1 Immunothérapies - partenariats

BMS partners again with the company behind Opdivo [Pharmafile]

Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs [EndPoints]

5.12.2 Immunothérapies - CAR-T

Cancer Patients With Little Time Left Wait for Gilead’s New Drug [Bloomberg]

5.12.4 Immunothérapies - Essais

One of Merck’s pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK [EndPoints]

Merck's Keytruda fails pivotal gastric cancer trial [Reuters]

Merck Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Gastric or Gastroesophageal Junction Adenocarcinoma [Merck]

5.12.8 Immunothérapies - Economie

Kyn Nabs $49M to Target Metabolism and Beat Other Cancer Drug Combos [Xconomy]

5.2 Pharma

Novartis announces Oncology head to retire [Novartis]

5.2.1 Pharma - Partenariats

Celgene, CRT strike mRNA translation cancer R&D pact [FierceBiotech]

5.2.3 Pharma - économie

New investors, including GV, boost Relay in $63M round [FierceBiotech]

Its underlying biology ‘too complicated’ for further investment, Atlas-seeded Raze signs off [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

FDA puts Bristol-Myers' Opdivo-Yervoy combo in fast lane for new kidney cancer nod [FiercePharma]

Biosimilars: Breaking Through to Cancer Treatment [Cancer Research Catalyst]

5.4 Traitements - Economie

NICE flip-flops to back J&J's Imbruvica in mantle cell lymphoma [FiercePharma]

Ibrutinib for treating relapsed or refractory mantle cell lymphoma [NICE]

6.1 Observation

Prior Cancers Common in Patients Newly Diagnosed with Cancer [NCI]

6.13 Soins palliatifs

ESMO Press Release: ESMO Publishes New Position Paper on Supportive and Palliative Care [ESMO]

6.8 Communication

An imbalanced infographic: Is this the best way to bring ‘the most exciting, up-to-date science to the world’s attention’? [HealthNewsReview]

6.9 Controverses

Viewpoint: Why so many scientific studies are flawed and poorly understood [Genetic Literacy Project]

Lung Cancer Causes 32% of All Cancer Deaths. Why Does It Get 10% of Research Funding? [Fortune]